EA201691638A1 - Новые способы индуцирования иммунного ответа - Google Patents

Новые способы индуцирования иммунного ответа

Info

Publication number
EA201691638A1
EA201691638A1 EA201691638A EA201691638A EA201691638A1 EA 201691638 A1 EA201691638 A1 EA 201691638A1 EA 201691638 A EA201691638 A EA 201691638A EA 201691638 A EA201691638 A EA 201691638A EA 201691638 A1 EA201691638 A1 EA 201691638A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immune response
new ways
inducing immune
administration
inducing
Prior art date
Application number
EA201691638A
Other languages
English (en)
Other versions
EA037405B1 (ru
Inventor
Уилльям Рипли мл. Баллоу
Арно Мишель Дидьелорен
Робберт Гэррит Ван дер Мост
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA201691638A1 publication Critical patent/EA201691638A1/ru
Publication of EA037405B1 publication Critical patent/EA037405B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Предложены способы и применения для индуцирования иммунного ответа, включающие по меньшей мере два введения иммуногенной композиции, где при втором введении дается более низкая доза, чем при первом введении, и где второе введение может быть в отсутствие адъюванта.
EA201691638A 2014-04-02 2015-04-02 Способ индуцирования иммунного ответа против малярии EA037405B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1405921.6A GB201405921D0 (en) 2014-04-02 2014-04-02 Novel methods for inducing an immune response
PCT/EP2015/057424 WO2015150568A1 (en) 2014-04-02 2015-04-02 Novel methods for inducing an immune response

Publications (2)

Publication Number Publication Date
EA201691638A1 true EA201691638A1 (ru) 2017-04-28
EA037405B1 EA037405B1 (ru) 2021-03-25

Family

ID=50737873

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691638A EA037405B1 (ru) 2014-04-02 2015-04-02 Способ индуцирования иммунного ответа против малярии

Country Status (18)

Country Link
US (3) US10624961B2 (ru)
EP (2) EP3125929B8 (ru)
JP (2) JP6645982B2 (ru)
KR (2) KR20230075525A (ru)
CN (2) CN106456739A (ru)
AR (1) AR099960A1 (ru)
AU (1) AU2015239025B2 (ru)
BE (1) BE1022355B1 (ru)
BR (2) BR112016022463A2 (ru)
CA (2) CA2943711A1 (ru)
EA (1) EA037405B1 (ru)
ES (2) ES2961840T3 (ru)
GB (1) GB201405921D0 (ru)
IL (1) IL247493B (ru)
MX (3) MX2016012982A (ru)
SG (1) SG11201607086QA (ru)
WO (2) WO2015150567A1 (ru)
ZA (1) ZA201605955B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
IE87414B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
CN114080393A (zh) 2019-06-05 2022-02-22 葛兰素史克生物有限公司 皂苷纯化
CN113125756B (zh) * 2020-07-15 2022-10-25 南京岚煜生物科技有限公司 抗体标准品赋值和抗原中和当量确定的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US152200A (en) * 1874-06-16 Improvement in garters
US1002607A (en) * 1905-08-28 1911-09-05 John Willard Taylor Paper pulley.
UA56132C2 (ru) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины
US8232255B2 (en) 2002-10-23 2012-07-31 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
RS52187B (en) 2004-10-14 2012-10-31 Crucell Holland B.V. Vaccines for the induction and stimulation of the immune response for malaria
PL2426141T3 (pl) * 2005-04-29 2015-02-27 Glaxosmithkline Biologicals Sa Sposób profilaktyki lub leczenia zakażenia m. tuberculosis
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2368568A1 (en) * 2006-11-01 2011-09-28 Immport Therapeutics, INC. Compositions and methods for immunodominant antigens
CL2008000611A1 (es) * 2007-03-02 2008-09-05 Glaxosmithkline Biolog Sa Procedimiento para fomentar respuesta inmunitaria frente a un patogeno que comprende administrar i) uno o mas polipeptidos inmunogenicos derivados del patogeno, ii) uno o mas vectores adenoviricos que comprenden uno o mas polinucleotidos que codifica
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
AU2009273133B2 (en) * 2008-07-25 2014-06-05 Glaxo Group Limited Novel compositions and methods
EA201100070A1 (ru) * 2008-07-25 2011-10-31 Глаксо Груп Лимитед Туберкулезный белок rv2386c, композиции и их применения
ES2602430T3 (es) * 2008-07-25 2017-02-21 Glaxosmithkline Biologicals S.A. Polipéptidos, polinucleótidos y composiciones para uso en el tratamiento de tuberculosis latente
SI2528621T1 (sl) * 2010-01-27 2017-01-31 Glaxosmithkline Biologicals S.A., Modificirani tuberkolozni antigeni
SG190731A1 (en) * 2010-12-14 2013-07-31 Glaxosmithkline Biolog Sa Mycobacterium antigenic composition
US20170056345A1 (en) * 2014-02-18 2017-03-02 Stc.Unm Booster drug therapy for mycobacterium infections
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
US10004793B2 (en) * 2014-04-24 2018-06-26 Statens Serum Institut M.tuberculosis vaccines
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Also Published As

Publication number Publication date
AR099960A1 (es) 2016-08-31
EP3125929A1 (en) 2017-02-08
CN106456738B (zh) 2021-06-29
US10688168B2 (en) 2020-06-23
AU2015239025A1 (en) 2016-09-22
US20170112914A1 (en) 2017-04-27
MX2016012932A (es) 2016-12-07
EP3125930B1 (en) 2020-12-02
JP6645982B2 (ja) 2020-02-14
EP3125930A1 (en) 2017-02-08
CA2943007A1 (en) 2015-10-08
IL247493B (en) 2022-08-01
EP3125929C0 (en) 2023-11-01
CN106456739A (zh) 2017-02-22
GB201405921D0 (en) 2014-05-14
JP2017511324A (ja) 2017-04-20
BE1022355B1 (fr) 2016-03-26
EP3125929B8 (en) 2023-12-27
EA037405B1 (ru) 2021-03-25
JP6655549B2 (ja) 2020-02-26
KR20160132115A (ko) 2016-11-16
CA2943007C (en) 2024-01-09
WO2015150567A1 (en) 2015-10-08
MX2016012982A (es) 2016-12-07
KR20230075525A (ko) 2023-05-31
US20170136110A1 (en) 2017-05-18
IL247493A0 (en) 2016-11-30
BE1022355A1 (fr) 2016-02-16
CN106456738A (zh) 2017-02-22
CA2943711A1 (en) 2015-10-08
EP3125929B1 (en) 2023-11-01
US10624961B2 (en) 2020-04-21
ES2853773T3 (es) 2021-09-17
US20200306353A1 (en) 2020-10-01
BR112016022787A2 (pt) 2018-03-27
SG11201607086QA (en) 2016-09-29
ES2961840T3 (es) 2024-03-14
WO2015150568A1 (en) 2015-10-08
MX2022013912A (es) 2022-12-13
JP2017511327A (ja) 2017-04-20
BR112016022463A2 (pt) 2017-10-10
US11951161B2 (en) 2024-04-09
ZA201605955B (en) 2019-04-24
AU2015239025B2 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
EA201691638A1 (ru) Новые способы индуцирования иммунного ответа
WO2015168379A3 (en) Combination vaccine devices and methods of killing cancer cells
DK3253865T3 (da) Fremgangsmåder til forbedring af virkningen af terapeutiske immunceller
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
EA201800148A1 (ru) Оспенная вакцина для лечения рака
EA201691429A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
MX2017002890A (es) Métodos y composiciones para potenciar respuestas inmunitarias.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
SG11202003796XA (en) Zika vaccines and immunogenic compositions, and methods of using the same
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
CL2018000609A1 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue.
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
DK3558391T3 (da) Immunkonjugater med adam9 som mål og fremgangsmåder til anvendelse deraf
SG11202004863QA (en) Zika vaccines and immunogenic compositions, and methods of using the same
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
EA201690378A1 (ru) Вакцинные композиции против наркотической зависимости
EA202090225A3 (ru) Модифицированные менингококковые полипептиды fhbp
ZA201700164B (en) Influenza virus vaccines and uses thereof

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM